Guidelines should not pool evidence from uncomplicated & severe COVID-19
A letter was published this week in The Lancet by four authors who are members of the COVID-19 Clinical Research Coalition. Prof. Nick White, Dr Nathalie Strub-Wourgaft, Prof. Abul Faiz, and Prof. Philippe Guérin make the case that assessments of drug efficacy in preventing COVID-19 and treating uncomplicated COVID-19 should not be based on data pooled with the treatment results of severely ill patients. The authors, who are also members of the coalition’s Steering Committee, note that studies to date have found major differences in therapeutic responses according to disease stage.
REPORT l Growing Concern on Vaccine Falsification
The Medicine Quality Research Group has published a new Medical Product Quality Report focusing on increasing issues around substandard and falsified COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.
DEADLINE EXTENDED: Call for nominations to ACT-Accelerator Therapeutics Partnership workstreams
The COVID-19 Clinical Research Coalition is working with the ACT-Accelerator Therapeutics Partnership to increase the representation of researchers from low- and middle-income countries in the Therapeutics Partnership’s workstreams. We are seeking researchers with relevant research expertise, technical competence, a commitment to the principles of equitable access for all, and a desire to represent the research priorities of low-resource settings in these workstreams.
Final report on ethics review mutual recognition in COVID-19 pandemic
Following a successful webinar on Ethics review mutual recognition, the Ethics Working Group of the COVID-19 Clinical Research Coalition is sharing the findings of a project, funded by the World Health Organization, aiming to review the challenges and opportunities of ethics review mutual recognition for COVID-19 multi-site research protocols.